EPIPHANY: Evaluation of PCD-CT Based Image Parameters in the Assessment and Quantification of Coronary Artery Disease

Sponsor
University Medical Center Mainz (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05877768
Collaborator
(none)
3,000
1
120
25

Study Details

Study Description

Brief Summary

The goal of this observational study is to learn about a new type of computed tomography (Photon-Counting Detector CT) in patients with coronary artery disease.

The main questions it aims to answer are:
  • How good is the image quality for the new CT

  • How accurate are measurements in the images of the new CT

  • Is there a relationship between measurements in the images and the management of the disease (e.g. new medication or additional investigations)

  • Is there a relationship between measurements in the images and the results of follow-up investigations

  • Is there a relationship between measurements in the images and the patient outcome

Participants will undergo normal clinical assessment of coronary artery disease and all data from the CT scan and additional investigations will be collected. There will be no additional investigations for the purpose of the study. After 1, 2 and 5 years, participants will be asked to answer a health questionaire.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Photon Counting Detector Coronary Computed Tomography Angiography

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
3000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
PCD-CT Registry: Evaluation of Photon Counting Detector-CT Based Image Parameters in the Assessment and Quantification of Coronary Artery Disease (EPIPHANY)
Anticipated Study Start Date :
Jun 30, 2023
Anticipated Primary Completion Date :
Jun 30, 2033
Anticipated Study Completion Date :
Jun 30, 2033

Arms and Interventions

Arm Intervention/Treatment
Coronary Artery Disease

Patients with suspected coronary artery disease and those with known coronary artery disease and the suspicion of progressive disease who undergo clinically indicated Coronary Computed Tomography Angiography on the Photon-Counting Detector CT will be enrolled after written consent. All data from the CT scan and potential additional investigations (e.g. invasive coronary angiographies) will be collected. There will be no additional investigations for the purpose of the study. After 1, 2 and 5 years, participants will be asked to answer a health questionaire.

Diagnostic Test: Photon Counting Detector Coronary Computed Tomography Angiography
Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
Other Names:
  • Photon-Counting Detector CT (Naeotom Alpha, Siemens Healthineers)
  • Outcome Measures

    Primary Outcome Measures

    1. Major Adverse Cardiac Events [From inclusion to a maximum follow-up of 5 years]

      Composite endpoint: major adverse cardiovascular event (MACE); defined as at least one of the following: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

    Secondary Outcome Measures

    1. Objective Image Noise of Photon-Counting Detector Coronary Computed Tomography Angiography (PCD-CCTA) [during the PCD-CCTA examination]

      Image Noise of PCD-CCTA measured objectively using measurements of CT values (HU).

    2. Objective Assessment of Noise-Power Spectra of PCD-CCTA [during the PCD-CCTA examination]

      Image Noise of PCD-CCTA measured objectively using noise-power spectra (W/Hz).

    3. Subjective Image Noise of PCD-CCTA [during the PCD-CCTA examination]

      Image Noise of PCD-CCTA judged subjectively on a 5-point Likert scale.

    4. Objective Vessel sharpness in PCD-CCTA [during the PCD-CCTA examination]

      Vessel sharpness in PCD-CCTA measured objectively using the slope of fitted double sigmoid curves (1/mm)

    5. Subjective Vessel sharpness in PCD-CCTA [during the PCD-CCTA examination]

      Vessel sharpness in PCD-CCTA judged subjectively on a 5-point Likert scale.

    6. Objective Image Quality in PCD-CCTA [during the PCD-CCTA examination]

      Objective Image Quality in PCD-CCTA measured objectively by contrast-to-noise ratio (HU/HU)

    7. Subjective Image Quality in PCD-CCTA [during the PCD-CCTA examination]

      Subjective Image Quality in PCD-CCTA judged subjectively on a 5-point Likert scale.

    8. Influence of BMI on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of Body Mass Index (BMI, kg/m^2) on image quality of the PCD-CCTA

    9. Influence of biological sex on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of patients biological sex (male/female) on image quality of the PCD-CCTA

    10. Influence of monoenergetic energy levels on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of monoenergetic energy levels (keV) on image quality of the PCD-CCTA

    11. Influence of slice thickness of reconstruction on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of slice thickness of reconstruction (mm) on image quality of the PCD-CCTA

    12. Influence of reconstruction kernel on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of reconstruction kernel (Bv/Br/Qr) on image quality of the PCD-CCTA

    13. Influence of kernel sharpness level on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of kernel sharpness level (40-90) on image quality of the PCD-CCTA

    14. Influence of radiation dose on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of radiation dose (mGy) on image quality of the PCD-CCTA

    15. Influence of the patients heart rate on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of the patients maximum, minimum and average heart rate (1/min) on image quality of the PCD-CCTA

    16. Influence of the acquisition type on image quality of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of the acquisition type (Sequential, Spiral, Ultra-High Resolution, Spectral) on image quality of the PCD-CCTA

    17. Quantitative analysis of Coronary Calcium Scoring from PCD-CCTA [during the PCD-CCTA examination]

      Quantitative analysis of Coronary Calcium volume (mm^3), mass (g) and resulting score according to the Agatston classification.

    18. Analysis of Stenosis Classification from PCD-CCTA [during the PCD-CCTA examination]

      Analysis of Coronary stenosis classification according to the Coronary Artery Disease-Reporting and Data System (CAD-RADS, 0-5, higher numbers indicating more severe stenosis).

    19. Quantitative analysis of Coronary Diameter Stenoses from PCD-CCTA [during the PCD-CCTA examination]

      Quantitative analysis of Coronary Diameter Stenoses (%) from PCD-CCTA

    20. Quantitative analysis of Coronary Area Stenoses from PCD-CCTA [during the PCD-CCTA examination]

      Quantitative analysis of Coronary Area Stenoses (%) from PCD-CCTA

    21. Quantitative analysis of computed Fractional Flow Reserve from PCD-CCTA [during the PCD-CCTA examination]

      Quantitative analysis of computed Fractional Flow Reserve (absolute number) from PCD-CCTA.

    22. Quantitative analysis of myocardial density from PCD-CCTA [during the PCD-CCTA examination]

      Quantitative analysis of myocardial density (HU) from PCD-CCTA.

    23. Quantitative analysis of myocardial iodine content from PCD-CCTA [during the PCD-CCTA examination]

      Quantitative analysis of myocardial iodine content (µg/cm^3) from PCD-CCTA.

    24. Quantitative analysis of extracellular volume fraction from PCD-CCTA [during the PCD-CCTA examination]

      Quantitative analysis of the extracellular volume fraction (%) from PCD-CCTA.

    25. Influence of BMI on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of Body Mass Index (BMI, kg/m^2) on quantitative parameters of the PCD-CCTA

    26. Influence of biological sex on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of patients biological sex (male/female) on quantitative parameters of the PCD-CCTA

    27. Influence of monoenergetic energy levels on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of monoenergetic energy levels (keV) on quantitative parameters of the PCD-CCTA

    28. Influence of slice thickness of reconstruction on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of slice thickness of reconstruction (mm) on quantitative parameters of the PCD-CCTA

    29. Influence of reconstruction kernel on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of reconstruction kernel (Bv/Br/Qr) on quantitative parameters of the PCD-CCTA

    30. Influence of kernel sharpness level on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of kernel sharpness level (40-90) on quantitative parameters of the PCD-CCTA

    31. Influence of radiation dose on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of radiation dose (mGy) on quantitative parameters of the PCD-CCTA

    32. Influence of the patients heart rate on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of the patients maximum, minimum and average heart rate (1/min) on quantitative parameters of the PCD-CCTA

    33. Influence of the acquisition type on quantitative parameters of the PCD-CCTA [during the PCD-CCTA examination]

      Influence of the acquisition type (Sequential, Spiral, Ultra-High Resolution, Spectral) on quantitative parameters of the PCD-CCTA

    34. Rates of patients undergoing further cardiac diagnostics [2 weeks after initial PCD-CCTA, 1-year follow-up, 2-year follow-up and final follow-up up to a max of 5 years]

      Rates of patients undergoing further cardiac diagnostics, such as additional CT or Invasive Coronary Angiography (ICA), Electrocardiography (ECG), Exercise ECG, Echo, Stress Echo, Magnetic Resonance Imaging (MRI) within 3 months following PCD-CCTA (defined as: related to these tests) and more than 3 months after PCD-CCTA until follow-up (unrelated to these tests).

    35. Rates of patients undergoing cardiac interventions [2 weeks after initial PCD-CCTA, 1-year follow-up, 2-year follow-up and final follow-up up to a max of 5 years]

      Cardiac interventions such as coronary revascularization by ICA, coronary artery bypass grafting (CABG), Valve replacement (operatively and interventional), other cardiothoracic surgeries, implantation of an cardioverter/defibrillator or cardiac resynchronization device, ablation, others

    36. Correlation and agreement of quantitative measurements from PCD-CCTA with ICA [ICA within 3 months of initial PCD-CCTA]

      Correlation and agreement of percent diameter stenosis quantification by PCD-CCTA in comparison to quantitative assessment from ICA.

    37. Correlation and agreement of non-invasive Fractional Flow Reserve from PCD-CCTA with invasive Fractional Flow Reserve from ICA [ICA within 3 months of initial PCD-CCTA]

      Correlation and agreement of non-invasively estimated Fractional Flow Reserve by Computed Tomography with invasive Fractional Flow Reserve

    38. Correlation and agreement of Percent diameter stenosis measurement from PCD-CCTA with Fractional Flow Reserve from ICA [ICA within 3 months of initial PCD-CCTA]

      Correlation and agreement of stenosis quantification by PCD-CCTA and invasive Fractional Flow Reserve.

    39. Correlation and agreement of Plaque composition assessment from PCD-CCTA with intracoronary techniques [ICA within 3 months of initial PCD-CCTA]

      Correlation and agreement of Plaque composition assessment from PCD-CCTA in comparison to intracoronary techniques such as optical coherence tomography (OCT) in patients who had both tests done.

    40. Correlation of quantitative PCD-CCTA parameters with the results of additional imaging ischemia tests [Imaging ischemia tests within 3 months of initial PCD-CCTA]

      Correlation of quantitative PCD-CCTA parameters with imaging ischemia tests in patients who had both PCD-CCTA and one of the following tests done: stress echo, stress Single Photon Emission Computed Tomography (SPECT), stress Positron Emission Tomography (PET), and stress MRI.

    41. Correlation of quantitative PCD-CCTA parameters with the results of additional other imaging tests [Imaging tests within 3 months of initial PCD-CCTA]

      Correlation of quantitative PCD-CCTA parameters with imaging tests in patients who had both PCD-CCTA and one of the following tests done: transthoracic echo, transesophageal echo, cardiac MRI.

    42. Patient management [at baseline, 1-year follow-up, 2-year follow-up and final follow-up up to a max of 5 years]

      Recommended and actually performed management based on PCD-CCTA

    43. Analysis of occurrence in Major Adverse Cardiac Events in subgroups [at baseline, 1-year follow-up, 2-year follow-up and final follow-up up to a max of 5 years]

      Composite outcome: Analysis of occurrence in MACE as a secondary outcome in following subgroups: CT plaque characteristic groups: high risk versus other plaques versus no plaques; Plaque burden groups: P1 vs. P2 vs. P3 vs. P4 according to the CAD-RADS 2.0 classification; Gender: male versus female; Age: occurrence of MACE in patient a) under 45 years, b) between 45 and 65 years and c) over 65 years; BMI: Patients with BMI a) under 25, b) between 25 and 30 and c) over 30;

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clinical indication for a coronary computed tomography angiography (CCTA) for the suspicion of coronary artery disease or the progression thereof

    • Written informed consent

    Exclusion Criteria:
    • Contraindications preventing the execution of the CCTA (e.g., pregnancy)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Medical Center Mainz Mainz Rhineland-Palatinate Germany 55116

    Sponsors and Collaborators

    • University Medical Center Mainz

    Investigators

    • Principal Investigator: Tilman Emrich, MD, University Medical Center Mainz

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Tilman Emrich, Dr. med., University Medical Center Mainz
    ClinicalTrials.gov Identifier:
    NCT05877768
    Other Study ID Numbers:
    • PCD-CT Registry
    First Posted:
    May 26, 2023
    Last Update Posted:
    May 26, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 26, 2023